STERIS plc (NYSE:STE) is highlighted as one of the best medical technology stocks to invest in, with Citizens reiterating its Market Outperform rating and $280 price target after STERIS’s Q3 FY2026 results. The company beat revenue expectations by 1% and maintained strong growth, with revenue up 7.1% and margins at 44.5%.

STERIS reported adjusted earnings per share of $2.53 in Q3 2026, meeting Wall Street expectations. Quarterly revenue reached $1.50 billion, exceeding estimates by 9% and driven by demand growth across various business lines. The company posted 8% organic revenue growth on a constant-currency basis, reaffirming its full-year fiscal 2026 guidance.

STERIS plc provides a range of medical technology products and services focused on infection prevention and procedural support, including sterilizers, surgical tables, endoscope reprocessors, and operating room integration systems. Despite potential as an investment, some believe certain AI stocks offer greater upside potential and less downside risk.

For more investment opportunities, check out “12 Best Foreign Stocks to Buy Right Now” and “11 Best AI Penny Stocks to Buy Right Now.” This article is originally published at Insider Monkey.

Read more at Yahoo Finance: STERIS plc (STE) Remains in Focus as Analysts Reaffirm Confidence